21 April 2020 - Larotrectinib has been given a positive opinion by NICE, following the submission of a revised price after it was previously rejected.

NICE has recommended Vitrakvi (larotrectinib), a treatment for many different cancer types, for use on the Cancer Drugs Fund.

Produced by Bayer, the medicine is a histology independent cancer treatment that targets all solid tumours with a neurotrophic tyrosine receptor kinase (NTRK) genetic mutation, regardless of where the primary tumour is in the patient’s body.

Read European Pharmaceutical Review article